Back to top

Analyst Blog

Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report) recently announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has rendered a positive opinion on Soliris (eculizumab) for orphan medicinal product designation for the treatment of neuromyelitis optica (NMO). Recently, the US Food and Drug Administration (FDA) rendered orphan drug designation to Soliris for the same indication.

We note that Soliris is approved in the US, EU and many other countries for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris has orphan drug designation for the treatment of PNH in the US, Europe, Japan and several other countries. The drug also has orphan drug status for aHUS in the US and the EU.

Soliris is the company’s only marketed product and is yet to get approval for the NMO indication in any country.

The drug recorded sales of $1.13 billion in 2012, up 45% and $338.9 million in the first quarter of 2013, up 38%.

Alexion is working on expanding Soliris’ label into additional indications like Shiga-toxin producing E. coli hemolytic uremic syndrome and myasthenia gravis. Alexion’s pipeline also includes asfotase alfa, ALXN1102/ALXN1103 and ALXN1007.

Alexion has been in the news recently with rumors doing the rounds about the company being a potential takeover target. This led to its stock price soaring more than 12% last week. Alexion currently carries a Zacks Rank #3 (Hold). Stocks in the biopharma space, which appear to be more attractive, include Jazz Pharmaceuticals Public Limited Company (JAZZ - Analyst Report) , Sarepta Therapeutics, Inc. (SRPT - Analyst Report) and Medivation, Inc. (MDVN - Analyst Report) with a Zacks Rank #1 (Strong Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%